Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease... Show more
SAVA is expected to report earnings to fall 52.63% to -27 cents per share on March 03
Q4'25
Est.
$-0.27
Q4'24
Missed
by $0.09
Q3'24
Beat
by $0.15
Q2'24
Beat
by $0.54
Q1'24
Beat
by $0.03
The last earnings report on March 03 showed earnings per share of -56 cents, missing the estimate of -47 cents. With 762.08K shares outstanding, the current market capitalization sits at 132.85M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. SAVA showed earnings on March 03, 2025. You can read more about the earnings report here.